Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofazimine inhalation - MannKind Corporation

Next Previous
Drug Profile

Clofazimine inhalation - MannKind Corporation

Alternative Names: MNKD-101; MNKD-102; QRM-003; QRM-007

Latest Information Update: 03 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qrumpharma
  • Developer MannKind Corporation
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Nontuberculous mycobacterium infections

Most Recent Events

  • 10 Nov 2025 Preclinical trials in Nontuberculous mycobacterium infections in USA (Inhalation, Dry powder)
  • 10 Nov 2025 MannKind Corporation plans a phase I trial for Nontuberculous mycobacterium infections (Inhalation, Dry powder)
  • 10 Nov 2025 Mannkind Corporation terminates phase III trials in Nontuberculous mycobacterium infections (Adjunctive treatment) in Japan, Taiwan, USA, Australia, South Korea due to futility (Inhalation) (NCT06418711)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top